Edesa Biotech, Inc. Stock price

Equities

EDSA

CA27966L3065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.192 USD -5.80% Intraday chart for Edesa Biotech, Inc. +2.49% -8.28%
Sales 2024 * - Sales 2025 * - Capitalization 13.3M
Net income 2024 * -8M Net income 2025 * -10M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-1.8 x
P/E ratio 2025 *
-2.52 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.2%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.80%
1 week+2.49%
Current month-9.23%
1 month-15.49%
3 months-6.64%
6 months-16.48%
Current year-8.28%
More quotes
1 week
3.93
Extreme 3.93
4.94
1 month
3.88
Extreme 3.88
4.96
Current year
3.88
Extreme 3.88
5.99
1 year
2.46
Extreme 2.4603
8.61
3 years
2.46
Extreme 2.4603
84.00
5 years
2.46
Extreme 2.4603
133.70
10 years
2.46
Extreme 2.4603
133.70
More quotes
Managers TitleAgeSince
Founder 53 07-06-11
President 46 15-08-31
Director of Finance/CFO 48 23-07-14
Members of the board TitleAgeSince
Director/Board Member 47 19-06-06
Director/Board Member 73 10-04-08
Director/Board Member - 23-05-22
More insiders
Date Price Change Volume
24-03-28 4.192 -5.80% 10,227
24-03-27 4.45 +8.01% 12,413
24-03-26 4.12 -1.39% 3,199
24-03-25 4.178 -2.38% 24,508
24-03-22 4.28 +4.65% 5,013

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.192 USD
Average target price
24 USD
Spread / Average Target
+472.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Edesa Biotech, Inc. - Nasdaq